Key regions: Germany, United States, India, Japan, United Kingdom
The Anti-Rheumatic Drugs market in Moldova has been steadily growing in recent years.
Customer preferences: Moldova has a high prevalence of rheumatoid arthritis, which is driving demand for anti-rheumatic drugs. Patients are increasingly seeking newer and more effective treatments to manage their symptoms. Additionally, there is a growing preference for biologic drugs, which are perceived to be more effective than traditional disease-modifying antirheumatic drugs (DMARDs).
Trends in the market: The market for anti-rheumatic drugs in Moldova is seeing a shift towards biologic drugs, which are expected to capture a larger share of the market in the coming years. However, the high cost of these drugs is a barrier to access for many patients. As a result, there is also a trend towards the use of biosimilars, which are more affordable alternatives to biologics. The market is also seeing the introduction of new drugs, including Janus kinase (JAK) inhibitors, which have shown promising results in clinical trials.
Local special circumstances: Moldova has a relatively small market for pharmaceuticals, which limits the availability of certain drugs. Additionally, the country has a high burden of non-communicable diseases, including rheumatoid arthritis, which puts pressure on the healthcare system to provide adequate treatment options. The lack of resources and infrastructure in the healthcare system also poses a challenge to the delivery of quality care.
Underlying macroeconomic factors: Moldova is one of the poorest countries in Europe, with a low GDP per capita and high levels of poverty. This limits the ability of patients to afford expensive drugs, including biologics. The country is also heavily reliant on imports for its pharmaceutical needs, which exposes it to fluctuations in exchange rates and supply chain disruptions. The regulatory environment for pharmaceuticals is also underdeveloped, which can lead to issues with quality control and counterfeit drugs.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
